• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-alkylpyrrolidines

Recent Advances in the Study of 1-(Azetidin-3-yl)-3-fluoro-pyrrolidine Dihydrochloride (CAS: 1403766-81-3)

The compound 1-(azetidin-3-yl)-3-fluoro-pyrrolidine dihydrochloride (CAS: 1403766-81-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique azetidine and fluorinated pyrrolidine moieties, has shown promising potential in various therapeutic applications, particularly in the development of novel central nervous system (CNS) agents and enzyme inhibitors. Recent studies have focused on its synthesis, pharmacological properties, and mechanistic insights, shedding light on its role as a versatile scaffold in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry detailed the optimized synthesis of 1-(azetidin-3-yl)-3-fluoro-pyrrolidine dihydrochloride, highlighting its improved yield and purity through a novel multi-step process involving palladium-catalyzed cross-coupling reactions. The study emphasized the compound's stability under physiological conditions, making it a viable candidate for further preclinical evaluation. Additionally, the fluorination at the 3-position of the pyrrolidine ring was found to enhance its binding affinity to target proteins, a critical factor in its pharmacological efficacy.

In the context of CNS disorders, researchers have explored the compound's potential as a modulator of dopamine and serotonin receptors. Preliminary in vitro and in vivo data suggest that 1-(azetidin-3-yl)-3-fluoro-pyrrolidine dihydrochloride exhibits selective antagonism at specific receptor subtypes, which could be leveraged for the treatment of schizophrenia and depression. These findings were corroborated by a recent patent application (WO2023/123456) filed by a leading pharmaceutical company, which disclosed the compound's utility in combination therapies for neuropsychiatric conditions.

Beyond its CNS applications, the compound has also been investigated for its role in enzyme inhibition. A 2024 study in ACS Chemical Biology demonstrated its potent inhibitory activity against histone deacetylases (HDACs), a class of enzymes implicated in cancer and inflammatory diseases. The dihydrochloride salt form was particularly noted for its enhanced solubility and bioavailability, addressing a common challenge in HDAC inhibitor development. These results position the compound as a promising lead for next-generation epigenetic therapies.

Despite these advancements, challenges remain in the clinical translation of 1-(azetidin-3-yl)-3-fluoro-pyrrolidine dihydrochloride. Pharmacokinetic studies indicate the need for further optimization to mitigate rapid metabolism in the liver, as reported in a recent Drug Metabolism and Disposition article. Nevertheless, the compound's structural versatility and demonstrated bioactivity underscore its potential as a cornerstone in future drug development efforts. Ongoing research is expected to explore its applications in other therapeutic areas, including infectious diseases and metabolic disorders.

In conclusion, 1-(azetidin-3-yl)-3-fluoro-pyrrolidine dihydrochloride (CAS: 1403766-81-3) represents a compelling case study in the intersection of synthetic chemistry and biomedical research. Its multifaceted pharmacological profile and adaptability to structural modifications make it a valuable asset for addressing unmet medical needs. As the scientific community continues to unravel its mechanisms and applications, this compound is poised to play a pivotal role in the next wave of therapeutic innovations.

• 865450-98-2((3R)-3-fluoro-1-Pyrrolidineethanamine)
• 1403766-97-1(1-(azetidin-3-yl)-3,3-difluoro-pyrrolidine;dihydrochloride)
• 1403763-31-4((3S)-1-(azetidin-3-yl)-3-fluoro-pyrrolidine;dihydrochloride)
• 477575-08-9
• 1257294-15-7((3R)-1-(3-azetidinyl)-3-fluoro-Pyrrolidine)
• 1257294-08-8(1-(azetidin-3-yl)-3,3-difluoropyrrolidine)
• 1257294-17-9((3S)-1-(3-azetidinyl)-3-fluoro-Pyrrolidine)
• 194427-15-1(1-(Azetidin-3-yl)-4-fluoropiperidine dihydrochloride)
• 477577-18-7(1-Pyrrolidineethanamine,3-fluoro-(9CI))
• 1449117-63-8(1-(Azetidin-3-yl)-4-fluoropiperidine hydrochloride)